Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial

Inclusion Criteria

Inclusion criteria:

- Histologically confirmed diagnosis of a recurrent primary malignant glioma

- Life expectancy of at least 3 months with normal hematological, liver and renal
function

Exclusion criteria:

- Pregnant and lactating patients

- Participation in any investigating drug study within 4 weeks preceding treatment
start or concurrent treatment with any other anti-cancer therapy

- Gastrointestinal dysfunction that could alter absorption or motility